The risk of outcomes
| Outcomes | Patients with outcome | HR (95% CI)* | Patients with outcome | HR (95% CI)* | ||
| JAKi (n=2676) | TNFi (n=2676) | IL-6i (n=967) | TNFi (n=967) | |||
| Disease incidence | ||||||
| COVID-19 | 264 | 290 | 1.058 (0.895 to 1.250) | 98 | 101 | 1.028 (0.779 to 1.358) |
| Medical utilisation | ||||||
| Hospitalisation | 261 | 244 | 1.194 (1.003 to 1.423) | 103 | 89 | 1.296 (0.976 to 1.721) |
| Critical care services | 69 | 63 | 1.237 (0.878 to 1.742) | 20 | 24 | 0.862 (0.476 to 1.560) |
| Mechanical ventilation | 36 | 30 | 1.373 (0.844 to 2.232) | 11 | 10 | 1.154 (0.490 to 2.718) |
| Mortality | ||||||
| Deceased | 87 | 69 | 1.440 (1.049 to 1.976) | 30 | 38 | 0.835 (0.517 to 1.348) |
| Adverse outcomes† | 292 | 264 | 1.242 (1.051 to 1.468) | 111 | 103 | 1.209 (0.924 to 1.581) |
Note: If the patient number is less than or equal to 10, the results show the count as 10.
Bold font indicates statistical significance.
*Patients in each cohort after propensity score matching performed on age at index, sex, race, socioeconomic status, lifestyles, comorbidities, medical utilisation, COVID-19 vaccination and medication usage.
†Including hospitalisation, critical care services, mechanical ventilation, or deceased.
IL-6i, interleukin 6 inhibitors; JAKi, Janus-associated kinase inhibitors; TNFi, tumour necrosis factor alpha inhibitors.